NCT07215520
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
Active, Not Recruiting
PHASE2Ages 18+InterventionalPreventionCastleVax Inc.
~200 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:NDV-HXP-S-KP.2COVID-19 mRNA Vaccine
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability of the NDV-HXP-S-KP.2 Vaccine Compared With an Approved mRNA COVID-19 Vaccine
Measured over Up to 180 days after vaccination
Conditions
Where it's being run
2 sites across 2 statesColorado1
Massachusetts1
Study leadership
- Michael Egan, PhD · STUDY_CHAIR · CastleVax Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Safety and Tolerability of the NDV-HXP-S-KP.2 Vaccine Compared With an Approved mRNA COVID-19 VaccineUp to 180 days after vaccination
Safety and tolerability of the NDV-HXP-S-KP.2 vaccine given intranasally and an approved mRNA COVID-19 vaccine given intramuscularly will be assessed in previously immunized adults. Outcomes include the percentage of participants with solicited local and systemic reactogenicity symptoms through 7 days, unsolicited adverse events through 30 days, and serious, medically attended, or special interest adverse events through 180 days. Clinically significant abnormal lab results (chemistry and hematology) will also be assessed through 7 days post-vaccination.